HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Discreet biotech Osanni Bio starts making noise with $190M series B for clinical push

An under-the-radar Bay Area biotech has brought in a $190 million series B with the goal of hatching a clutch of new companies to fly its drug candidates forward.

By FierceBiotech · Jun 24, 2026 · via FierceBiotech
Discreet biotech Osanni Bio starts making noise with $190M series B for clinical push

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Revance taps dancer Julianne Hough to choreograph social media push for Botox rival
Julianne Hough is the new face of Revance's Botox rival Daxxify. The company has enlisted the dancer, actress …
Jun 24, 2026
Serapha Bio launches with $230M and YolTech base-editing therapy for AATD
The WeekBriefing
Serapha Bio launches with $230M and YolTech base-editing therapy for AATD
Serapha Bio forms via Boundless Bio reverse merger, backed by $230M to advance SERP-01, a China-derived base-e…
Jun 24, 2026
Opinion: How I used public radio to recruit 20,000 participants for a peer-reviewed study on walking breaks
The WeekSTAT News ↗
Opinion: How I used public radio to recruit 20,000 participants for a peer-reviewed study on walking breaks
"With the right structure, Americans will roll up their sleeves, do the science, and trust the result," Manous…
Jun 24, 2026